Lineage Cell Therapeutics (LCTX) Profit After Tax (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Profit After Tax of -$4.8 million for Q1 2026, down 15.7% year-over-year from -$5.7 million in Q1 2025, and down 759.64% quarter-over-quarter from $726000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Profit After Tax (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 15.7% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$64.2 million (down 297.49% YoY), while the FY2025 annual figure was -$63.5 million, down 241.91% from the prior year.
- Profit After Tax for Q1 2026 stood at -$4.8 million, down from $726000.0 in the prior quarter.
- The five-year high for Profit After Tax was $726000.0 in Q4 2025, with the low at -$30.4 million in Q2 2025.
- The 5-year median for Profit After Tax is -$5.8 million (2024), against an average of -$7.9 million.
- Peak annual rise in Profit After Tax reached 122.37% in 2025, while the deepest fall reached 891.4% in 2025.
- Lineage Cell Therapeutics' Profit After Tax stood at -$6.4 million in 2022, then grew by 24.85% to -$4.8 million in 2023, then jumped by 32.02% to -$3.2 million in 2024, then soared by 122.37% to $726000.0 in 2025, then slumped by 759.64% to -$4.8 million in 2026.
- Business Quant data shows LCTX's Profit After Tax at -$4.8 million in Q1 2026, $726000.0 in Q4 2025, and -$29.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 1.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | -4.79 Mn |
| Dec 31, 2025 | 726,000.00 |
| Sep 30, 2025 | -29.75 Mn |
| Jun 30, 2025 | -30.36 Mn |
| Mar 31, 2025 | -4.14 Mn |
| Dec 31, 2024 | -3.25 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Mar 31, 2024 | -6.56 Mn |
| Dec 31, 2023 | -4.78 Mn |
| Sep 30, 2023 | -7.16 Mn |
| Jun 30, 2023 | -5.23 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -6.35 Mn |
| Sep 30, 2022 | -6.07 Mn |
| Jun 30, 2022 | -6.76 Mn |
| Mar 31, 2022 | -7.09 Mn |
| Dec 31, 2021 | -28.99 Mn |
| Sep 30, 2021 | -7.82 Mn |